A randomized, phase III trial to determine the effect of consolidation with rituximab (IDEC C2B8-Mabthera) in patients with CD20+ follicular or mantle cell lymphoma having received induction therapy with rituximab weekly x 4.

Trial Profile

A randomized, phase III trial to determine the effect of consolidation with rituximab (IDEC C2B8-Mabthera) in patients with CD20+ follicular or mantle cell lymphoma having received induction therapy with rituximab weekly x 4.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Aug 2011

At a glance

  • Drugs Rituximab (Primary)
  • Indications Follicular lymphoma; Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Nov 2009 Status changed from active, no longer recruiting to completed.
    • 12 Oct 2009 Long-term follow-up results presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.
    • 30 May 2009 Results presented at ASCO 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top